3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
2
Terminated
2
Recruiting
2
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
10
Thoracic
6
Dermatologic
3
Other solid neoplasm
2
Head & Neck
2
Genitourinary
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
CNS
1
Conditions
Turcot syndrome
1
Rectal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
pembrolizumab
45
Paclitaxel
45
Carboplatin
39
Magnetic Resonance Spectroscopy
28
olaparib
27
Specimen Handling
26
Cisplatin
24
Bevacizumab
20
Nivolumab
18
Taxes
17
Biopsy
16
Gemcitabine
13
Cyclophosphamide
13
durvalumab
12
Immunoglobulin G
11
Doxorubicin
11
Disulfides
11
Surveys and Questionnaires
10
niraparib
9
liposomal doxorubicin
9
dostarlimab
9
Radiotherapy
8
Brachytherapy
8
lenvatinib
7
fludarabine
7
atezolizumab
7
Letrozole
7
Docetaxel
7
cediranib
6
Platinum
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Immune Checkpoint Inhibitors
×
Gynecologic
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled